Emerging evidence suggests that the Notch/Delta-like ligand 4 (DLL4) pathway may offer important new targets for anti-angiogenesis approaches. In this study, we investigated the clinical and biological significance of DLL4 in ovarian cancer. DLL4 was overexpressed in 72% of tumors examined where it was an independent predictor of poor survival. 
Introduction
Ovarian cancer remains the leading cause of death from a gynecologic malignancy among women in the United States. Although tumor-reductive surgery and taxane-and platinum-based chemotherapy regimens are effective treatments for primary disease in the majority of patients with this cancer, recurrence is common and often leads to death. New therapeutic agents are needed to improve survival rates and, eventually, to cure this deadly disease.
The progressive growth of primary tumor and metastasis is dependent on angiogenesis.
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, plays a pivotal role in developmental, physiological, and pathological neovascularization (1) (2) (3) . Targeting the tumor vasculature is a particularly attractive strategy because of the presumed genetic stability of endothelial cells (4) . The recent success of anti-angiogenic therapy with bevacizumab in solid tumors, including ovarian cancer, has confirmed the clinical viability of this approach (5) . Despite initial responses, however, most patients eventually experience tumor progression resulting in their death, mainly due to development of drug resistance. The precise molecular mechanisms underlying clinical resistance to anti-VEGF therapies are not well understood. Drug resistance can arise because of alterations in pharmacokinetics, cancer cell−specific abnormalities, and/or alterations in the tumor microenvironment (6) (7) (8) . Therefore, additional targets for anti-angiogenesis strategies are urgently needed.
The Notch signaling pathway has recently been implicated in tumor angiogenesis, including vessel maturation, pericyte recruitment, branching and cell differentiation, proliferation, survival, and apoptosis. In mammalian cells, this pathway comprises five transmembrane Notch ligands Dll4 is an endothelium-specific ligand expressed at sites of vascular development and angiogenesis. Dll4 expression has previously been shown to be upregulated within the vasculature of breast, renal, and bladder cancers (9) . It has been suggested that VEGF induces Dll4/Notch signaling while Dll4/Notch signaling modulates the VEGF pathway, that Dll4 and VEGF merge to be the "yin and yang" of angiogenesis (10, 11, 12) . Recently, some studies have reported that Dll4 blockade inhibits tumor growth by inducing nonproductive angiogenesis manifested by increased vascular density and decreased perfusion in tumors. The precise mechanism of inhibition has not been elucidated, however, and the biological significance of Dll4 in ovarian cancer, especially VEGF-resistant ovarian cancer, is not well understood.
In this study, we examined the clinical, functional, and biological significance of Dll4 in ovarian cancer angiogenesis and tumor progression by using therapeutically relevant Dll4 silencing. Our findings indicate that Dll4 is a potential target for anti-angiogenic therapeutic strategies. paraffin-embedded epithelial ovarian cancer specimens from patients who were treated with an anti-VEGF agent (aflibercept or bevacizumab) were obtained from the Gynecologic Oncology tumor bank.
Immunohistochemical staining.
Immunohistochemical staining for Dll4 (1:200 dilution) was quantified by two investigators in a blinded fashion on the basis of percentage of positively stained tumor cells and staining intensity. The Dll4 antibody, which reacts with both mouse and human Dll4, was obtained from Rockland Immunochemicals for Research (Gilbertsville, PA). For the negative control, we used PBS instead of primary antibody. Dll4 expression in the endothelial cell compartment was defined as more than 25% of cells staining positive. The endothelial Dll4 score was dichotomized, with a positive score consisting of the presence of staining with moderate or strong intensity. In short, an overall score (OS 0-3) was generated based on the percentage of positively stained cells plus the intensity of staining (13) .
Cell lines and culture. A2780, SKOV3ip, OVCAR3, IGROV, and 2774 human epithelial ovarian cancer cells and pericyte-like cells (10T1/2) were maintained as described previously (14) . The derivation and characterization of murine ovarian endothelial cells (MOEC) have been described Western Blot Analysis. Western blot analysis was performed as previously reported (16, 17) .
DNA extraction and methylation analysis. DNA was extracted from MOEC using standard phenol-chloroform methods. MOEC were treated with immobilized Dll4 (1, 10, or 20 μg/mL). Other MOEC were treated with the demethylating agent azacytidine (AZA; 25 μM), immobilized Dll4 (10 μg/mL), or a combination of the two for 48 hours. Methylation status was determined by methylation-specific PCR using a methylation kit (EZ-96 gold; Zymo Research, Orange, CA).
MethPrimer software was used for prediction of the CpG island of VEGF receptor 2 (VEGFR2; NM-002253.2) and design of methylation-specific primers. The sequences of primers for methylated VEGFR2 at the promoter region were TGTTTTTA-GATGCGATTTGTCGTTC Jose, CA). The membrane invasion culture system chamber was used to measure the in vitro migration ability of cells, as previously described by our group (16, 17) . Statistical analysis. Differences in continuous variables such as mean body weight, tumor weight, MVD and vessel maturation, tumor cell proliferation, and intratumoral hypoxia were analyzed using the Mann-Whitney rank sum test. Statistical analyses were performed using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL). A two-tailed p<0.05 was considered statistically significant. Kaplan-Meier survival plots were generated and comparisons between survival curves were made using the log-rank statistic. 
Results
Clinical significance of Dll4 in ovarian cancers. Before investigating the biological significance of Dll4, we examined its clinical significance in ovarian carcinoma by using immunohistochemical peroxidase staining in 84 tumor samples (Fig. 1a) . The mean age of patients was 59.3 years (range, 36-88); 83% of tumors were of serous histology and 91% of high-grade histology. Eighty-eight percent of patients had advanced stage disease and 59% had Given Dll4's role in ovarian cancer progression and tumor angiogenesis, we next examined whether Dll4 expression is related to response to anti-VEGF therapy. Dll4 immunostaining was performed on 24 available tumor samples from patients treated with a regimen that included either aflibercept or bevacizumab. Patients whose disease responded to the anti-VEGF treatment had lower levels of Dll4 than those who had stable or progressive disease (Fig.1c) .
This finding further supports the role of Dll4 in modulating response to VEGF-targeted therapies. (Fig. 2c, d ), but not under normoxic conditions (data not shown), which is consistent with previous reports (9) . These results suggest that there may be a counter-regulatory mechanism within the tumor microenvironment, which may function to reduce responsiveness to VEGF-targeted agents.
Effect of VEGF and hypoxia on

Effect of Dll4 expression on function of ovarian cancer and endothelial cells
To determine the functional role of Dll4 in MOEC and ovarian cancer cells, we treated MOECs with immobilized Dll4 as an agonist for 48 or 72 hours and tested the expression of VEGFR2 by RT-PCR. Immobilized Dll4 downregulated VEGFR2 at 72 hours (Fig. 3a, and 3b) , supporting the existence of a negative feedback effect of Dll4 on VEGFR2 expression, which in turn might reduce sensitivity to anti-VEGF treatment. At the cellular level, we investigated whether Dll4 affects proliferation and migration of MOECs. Treatment with VEGF or Dll4 increased MOECs proliferation by 3.6-and 2.6-fold, respectively, compared with controls. However, treatment with Dll4 inhibited VEGF-induced proliferation by 1.5-fold compared to treatment with VEGF alone (Supplementary Fig. 1a ; p>0.05). The effect of immobilized Dll4 on proliferation of the A2780 cells was also investigated and there was a slight increase in proliferation (Supplementary Fig.   1d ). Furthermore, silencing Dll4 expression with Dll4 siRNA inhibited proliferation of A2780 ovarian cancer cells by 2.1-fold compared with the control and Dll4 was silenced by >80% in the A2780 cells (Supplementary Fig. 1b) . We also investigated the effects of treatment with Fig. 1c ).
Dll4-mediated downregulation of VEGFR2 through promoter methylation. To identify potential mechanisms underlying the decrease in VEGFR2 expression following Dll4 exposure under hypoxic conditions, we considered whether the effects could be epigenetic in nature. We examined whether there is an increase in VEGFR2 promoter methylation in MOECs following exposure to immobilized Dll4 as an agonist under hypoxic conditions. Methylation-specific PCR showed that Dll4 blockade can induce VEGFR2 methylation in MOECs in a dose-dependent manner (Fig. 4a, b) . Furthermore, methylation-specific PCR showed that methylation of VEGFR2 was increased by 1.7-fold in MOECs treated with Dll4 and decreased by 2.4 fold in MOECs treated with demethylating agent AZA and immobilized Dll4, compared to that in Dll4 treated MOECs (Fig.4c,d ).
In vivo Dll4 gene silencing. On the basis of our in vitro findings, we next asked whether Dll4 silencing in combination with anti-VEGF treatment in vivo would affect tumor growth and angiogenesis. Moreover, to address the biological significance of tumor versus endothelial cell Dll4 expression, we used human (tumor) and mouse (endothelial) Dll4 siRNA in the A2780 and SKOV3ip1 models of ovarian cancer. We also examined Dll4 protein expression in vivo in the SKOV3ip1 and A2780 models (Fig.2b) . Dll4 was expressed in the tissues from both SKOV3ip1 and A2780 ovarian cancer models, which might be reflective of induction under hypoxic conditions. Seven days after tumor cell injection, mice were randomized into eight treatment groups. Single treatment with mouse or human Dll4 siRNA significantly respectively (p<0.05 for both, Figure 5a ). In the same model, treatment with a combination of mouse and human Dll4 siRNA inhibited tumor growth to a greater degree than either siRNA alone, but the difference was not statistically significant. Bevacizumab alone reduced tumor weight by 76% compared to control (p<0.05). Neither mouse nor human Dll4 siRNA alone significantly enhanced the tumor-inhibiting effect of bevacizumab. However, the combination of mouse and human Dll4 siRNA plus bevacizumab resulted in the greatest inhibition of tumor growth, reducing tumor weight by 87% (p<0.05) compared to control, and by 46% compared to bevacizumab alone. The effects of Dll4 siRNA were similar in the SKOV3ip1 tumor model (Fig. 5b) . We also examined the effects of treatment on the number of tumor nodules and body weight of mice. The number of tumor nodules was significantly decreased following treatment in the bevacizumab alone, bevacizumab combined with mDll4 or hDll4 alone and bevacizumab combined with mDll4 and hDll4 siRNA in SKOV3ip1 model, in comparison to control (p<0.05, data not shown). In the A2780 model, the tumor nodule numbers were significantly decreased in the hDll4 siRNA treated group, compared to control.
However, there was no significant difference in the number of nodules between the hDll4 treated, and mDll4/hDll4 siRNA treated groups. There was no significant difference in the mean mouse weight between any of the different treatment groups (data not shown). These data suggest that Dll4 plays a functionally significant role in both the tumor and endothelial compartments.
Effect of Dll4 blockade on microvessel density, vessel maturation, tumor cell proliferation, and intratumor hypoxia. To identify potential mechanisms underlying the efficacy of Dll4 and VEGF blockade, we first examined their potential effects on angiogenesis.
As shown in Figure 6a , MVD was significantly increased in the group treated with mouse Dll4 siRNA, while it was significantly decreased in the group treated with human Dll4 siRNA (P<0.05 
comparison to control (p<0.05). MVD was decreased by bevacizumab monotherapy compared to control (p<0.05) and decreased even further when the anti-VEGF agent was combined with mouse and human Dll4 siRNA (p<0.05).
It has been reported that Dll4 plays an important role in pericyte recruitment (19) . We examined the extent of pericyte coverage using dual immunofluorescence staining for desmin (a pericyte marker) and CD31. As shown in Figure 6b , pericyte coverage was significantly decreased in the group treated with mouse Dll4 siRNA (P<0.05) vs. control, but was not altered in other treatment groups. To determine the effect of Dll4 blockade on tumor cell proliferation, we performed immunohistochemical staining for PCNA. As shown in Figure 6c , PCNA was significantly decreased in groups treated with mouse or human Dll4 alone or in combination (P<0.05 in all), compared to control. Proliferation was decreased by bevacizumab monotherapy, bevacizumab combined with mouse, or human Dll4 siRNA, or both mouse and human Dll4 siRNA compared to control (p<0.05), and decreased even further when it was combined with mouse and human Dll4 siRNA (p<0.05 vs. bevacizumab).
Because it has been suggested that blockage of Dll4 inhibits tumor growth and produces nonproductive angiogenesis, which is accompanied by increased intratumoral hypoxia (11), we measured viable hypoxic areas by staining tumor sections with pimonidazole. As shown in 
Discussion
The key findings of this study are that Dll4 overexpression was significantly associated with worse overall patient survival and was a predictor of response to anti-VEGF treatment. Whether activated Dll4/Notch signaling has an effect on proliferation of endothelial cells is not fully understood. Some studies have reported that blockage of the Notch signaling pathway was associated with enhanced angiogenic sprouting and branching, resulting in marked increase in tumor vessel density, but decrease in vessel function (11, 12) . We show here that MVD was significantly increased by blockage of mouse Dll4, which is consistent with other reports (11) .
MVD was decreased, however, by silencing tumor Dll4 in the tumor cells can overcome effect of silencing endothelial Dll4 on increasing tumor vessel density.
Dll4 and VEGF merge to be the yin and yang of angiogenesis (24, 25) . VEGF-induced Dll4/Notch signaling can induce a negative feedback loop in which VEGF induces Dll4, which in turn activates Notch in neighboring endothelial cells to suppress VEGFR2 levels. Decreased expression of VEGFR2 by activated Notch/Dll4 signaling may be explained by epigenetic modification of the VEGFR2 gene. Our in vitro findings support the suggestion that Dll4 can suppress VEGFR2 expression in endothelial cells. Prior to our work, the mechanism by which Dll4 suppresses VEGFR2 expression in endothelial cells was not known. It has been suggested that the Notch intracellular domains of Notch receptors and Notch-targeted genes (Hes1 and Hey1) might be involved in downregulation of VEGFR2, possibly through binding on the VEGFR2 promoter region, especially at GC-rich regions. We show here, for the first time, that Dll4 can directly increase VEGFR2 methylation levels in endothelial cells, which in turn might inhibit response to VEGF. We searched our previous microarray analysis of tumor endothelial cells for genes that could potentially regulate methylation (26) . EZH2 (16, 26) and DNMT were among the genes that were overexpressed in tumor endothelial cells. We also examined whether DNMT is required for VEGFR2 methylation in MOECs, and our findings suggest that AZA at least partially inhibits VEGFR2 methylation induced by immobilized Dll4, and that DNMT 
